董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dennis M. McGrath | 男 | President, Chief Financial Officer and Director | 60 | 80.88万美元 | 未持股 | 2017-03-30 |
| Stephen P. Connelly | 男 | Director | 65 | 未披露 | 未持股 | 2017-03-30 |
| Lewis C. Pell | 男 | Non-Executive Chairman of the Board of Directors | 73 | 未披露 | 未持股 | 2017-03-30 |
| Yoav Ben Dror | 男 | Non-Executive Vice Chairman of the Board of Directors | 64 | 未披露 | 未持股 | 2017-03-30 |
| Dolev Rafaeli | 男 | Chief Executive Officer and Director | 53 | 未披露 | 未持股 | 2017-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dennis M. McGrath | 男 | President, Chief Financial Officer and Director | 60 | 80.88万美元 | 未持股 | 2017-03-30 |
| Dolev Rafaeli | 男 | Chief Executive Officer and Director | 53 | 未披露 | 未持股 | 2017-03-30 |
董事简历
中英对照 | 中文 | 英文- Dennis M. McGrath
-
Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
Dennis M. McGrath,has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial-stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), Cagent Vascular, LLC and BioVector, Inc. Formerly from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and as Chairman of the Board of Trustees of Manor College. - Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
- Dennis M. McGrath,has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial-stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), Cagent Vascular, LLC and BioVector, Inc. Formerly from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and as Chairman of the Board of Trustees of Manor College.
- Stephen P. Connelly
-
Stephen P. Connelly于2007年5月3日被任命到我们董事会任职。他于2001年8月加入医疗技术和设备公司Viasys Healthcare, Inc.，从2002年11月到2004年8月担任总裁兼首席运营官。此外，他是Americas（美洲）的前任高级副总裁兼总经理，是Rhone Poulenc Rorer执行委员会（Executive Committee）的成员。他的广泛背景包括在医疗设备和制药领域的快速发展的市场驱动业务的规划、开发和管理中拥有超过25年的经验。自1999年以来他是St. Joseph's University的副教授，教育霍伯商学院（Haub School of Business）MBA（工商管理硕士）课程的国际管理和全球战略。此外，他有多样化和全面的商业背景（在战略和战术业务开发、合资、合并、收购和公司合作、构建和财务等领域拥有专业知识）。他精通高科技产品和流程的营销、销售、综合管理、研究和开发的各个方面。他具有丰富的国际经验，住在亚洲，负责许多发达国家的操作损益表。
Stephen P. Connelly was appointed to our Board of Directors on May 3 2007. Mr. Connelly joined Viasys Healthcare, Inc., a medical technology and device company in August 2001 and served as President and Chief Operating Officer from November 2002 until August 2004. In addition, Mr. Connelly was formerly Senior Vice President and General Manager of the Americas as well as a member of the Executive Committee of Rhone Poulenc Rorer. Mr. Connelly’s broad background includes over twenty-five years of experience in the planning, development and management of rapid-growth marketing-driven businesses in the medical device and pharmaceutical fields. Since 1999 Mr. Connelly has been an adjunct professor at St. Joseph’s University, teaching international management and global strategy in the MBA program in the Haub School of Business. In addition, Mr. Connelly has a diverse and comprehensive business background, with expertise in such areas as strategic and tactical business development, joint ventures, mergers, acquisitions and corporate partnering, structuring and finance. Mr. Connelly is well-versed in every aspect of marketing, sales, general management, research and development of high-technology products and processes. Mr. Connelly possesses extensive international experience, having lived in Asia and having had operational P&L responsibility in many developed countries. Mr. Connelly was selected to serve on the Company’s board because of his twenty-five years’ background in the medical device industry and his experience in business development. Mr. Connelly has a Bachelor’s in Business Administration with a concentration in Marketing from The University of Notre Dame and a Master’s in Business Administration from Syracuse University. - Stephen P. Connelly于2007年5月3日被任命到我们董事会任职。他于2001年8月加入医疗技术和设备公司Viasys Healthcare, Inc.，从2002年11月到2004年8月担任总裁兼首席运营官。此外，他是Americas（美洲）的前任高级副总裁兼总经理，是Rhone Poulenc Rorer执行委员会（Executive Committee）的成员。他的广泛背景包括在医疗设备和制药领域的快速发展的市场驱动业务的规划、开发和管理中拥有超过25年的经验。自1999年以来他是St. Joseph's University的副教授，教育霍伯商学院（Haub School of Business）MBA（工商管理硕士）课程的国际管理和全球战略。此外，他有多样化和全面的商业背景（在战略和战术业务开发、合资、合并、收购和公司合作、构建和财务等领域拥有专业知识）。他精通高科技产品和流程的营销、销售、综合管理、研究和开发的各个方面。他具有丰富的国际经验，住在亚洲，负责许多发达国家的操作损益表。
- Stephen P. Connelly was appointed to our Board of Directors on May 3 2007. Mr. Connelly joined Viasys Healthcare, Inc., a medical technology and device company in August 2001 and served as President and Chief Operating Officer from November 2002 until August 2004. In addition, Mr. Connelly was formerly Senior Vice President and General Manager of the Americas as well as a member of the Executive Committee of Rhone Poulenc Rorer. Mr. Connelly’s broad background includes over twenty-five years of experience in the planning, development and management of rapid-growth marketing-driven businesses in the medical device and pharmaceutical fields. Since 1999 Mr. Connelly has been an adjunct professor at St. Joseph’s University, teaching international management and global strategy in the MBA program in the Haub School of Business. In addition, Mr. Connelly has a diverse and comprehensive business background, with expertise in such areas as strategic and tactical business development, joint ventures, mergers, acquisitions and corporate partnering, structuring and finance. Mr. Connelly is well-versed in every aspect of marketing, sales, general management, research and development of high-technology products and processes. Mr. Connelly possesses extensive international experience, having lived in Asia and having had operational P&L responsibility in many developed countries. Mr. Connelly was selected to serve on the Company’s board because of his twenty-five years’ background in the medical device industry and his experience in business development. Mr. Connelly has a Bachelor’s in Business Administration with a concentration in Marketing from The University of Notre Dame and a Master’s in Business Administration from Syracuse University.
- Lewis C. Pell
-
Lewis C. Pell，他是Vision-Sciences公司的共同创始人，并一直担任董事会主席（2005年以来）。他于2013年6月14日由董事会任命为首席执行官。2005年之前，他曾担任我们董事会的副主席（1992年以来）。他是一些私营医疗设备公司的创始人、主席兼董事，也是Photomedex公司（上市皮肤病公司）的主席。
Lewis C. Pell was appointed to our Board of Directors and was unanimously elected to serve as Non-Executive Chairman of the Board on December 12 2011 and is the Chairman of the Compensation Committee. Mr. Pell was a member of Radiancy’s Board since 1998. Mr. Pell has founded over a dozen successful medical technology companies during the past three decades. In 1979 he founded Pentax Precision Instruments, which was sold to Asahi Optical Co. in 1990. In 1983 he founded American Endoscopy Inc., which was sold to C.R. Bard, Inc. BCR-NYSE in 1986. In 1984 he founded Versaflex Inc., which was sold to Medtronic in 1988. In 1989 he founded Heart Technology Corp., which went public in the U.S. in 1992 and was sold to Boston Scientific Corp. (BSX-NYSE) in 1995. In 1991 he founded InStent Inc., which became a public company in 1995 and was sold to Medtronic in 1996. In 1994 he founded Influence Inc., which was sold to American Medical Systems Inc. in 1999. Working with Dr. Shlomo Ben-Haim, Mr. Pell founded Biosense Inc. in 1994 which was sold to Johnson & Johnson in 1997. He is currently chairman and an investor for a number of private medical device companies. In 1992 he founded Vision-Sciences, Inc. which merged with Urolplasty, Inc. in 2015 to become Cogentix Medical, Inc. (CGNT NASDAQ) for which he is a director. Mr. Pell has a B.S. in political science from Brooklyn College and over 20 years of experience in the medical technology industry. - Lewis C. Pell，他是Vision-Sciences公司的共同创始人，并一直担任董事会主席（2005年以来）。他于2013年6月14日由董事会任命为首席执行官。2005年之前，他曾担任我们董事会的副主席（1992年以来）。他是一些私营医疗设备公司的创始人、主席兼董事，也是Photomedex公司（上市皮肤病公司）的主席。
- Lewis C. Pell was appointed to our Board of Directors and was unanimously elected to serve as Non-Executive Chairman of the Board on December 12 2011 and is the Chairman of the Compensation Committee. Mr. Pell was a member of Radiancy’s Board since 1998. Mr. Pell has founded over a dozen successful medical technology companies during the past three decades. In 1979 he founded Pentax Precision Instruments, which was sold to Asahi Optical Co. in 1990. In 1983 he founded American Endoscopy Inc., which was sold to C.R. Bard, Inc. BCR-NYSE in 1986. In 1984 he founded Versaflex Inc., which was sold to Medtronic in 1988. In 1989 he founded Heart Technology Corp., which went public in the U.S. in 1992 and was sold to Boston Scientific Corp. (BSX-NYSE) in 1995. In 1991 he founded InStent Inc., which became a public company in 1995 and was sold to Medtronic in 1996. In 1994 he founded Influence Inc., which was sold to American Medical Systems Inc. in 1999. Working with Dr. Shlomo Ben-Haim, Mr. Pell founded Biosense Inc. in 1994 which was sold to Johnson & Johnson in 1997. He is currently chairman and an investor for a number of private medical device companies. In 1992 he founded Vision-Sciences, Inc. which merged with Urolplasty, Inc. in 2015 to become Cogentix Medical, Inc. (CGNT NASDAQ) for which he is a director. Mr. Pell has a B.S. in political science from Brooklyn College and over 20 years of experience in the medical technology industry.
- Yoav Ben Dror
-
Yoav Ben Dror被任命为我司董事，并于2011年12月12日被选为董事会非执行副主席。Ben-Dror博士从2006年开始担任Radiancy的董事会主席。他是一位拥有超过30年技术、医疗设备与金融创新领域经验的企业家。他目前担任以下公司的董事：Dagon Batey-Mamguroth Le-Israel Ltd silo houses, Final Inc.（高频金融算法技术）， Fitango Inc.（社交网络），Neurotech Solutions Ltd.（专注于多动症的人类认知与行为），和Impact First Investments Ltd.（专注于社会投资的投资管理公司）。他担任支持青年企业家的Keren Shemesh基金会（其与青年商业国际（Youth Business International，YBI ）合作，后者为帮助青年企业家将想法转变为成功的且可持续的小型企业的基金会）董事，担任Hatnuah Hezrachit Hachadasha Ltd.的董事（社交活动），担任Hecht-Zilzer Trust（慈善机构）的理事。在这之前，Ben-Dror博士担任以下公司的董事：Cellcom Israel Ltd.（纽交所代码：CEL），Dubek Ltd.（烟草公司）与Magic Box Ltd.（金融算法技术公司），并担任以色列霍龙工学院（Holon Institute of Technology，H.I.T.）的校董会董事，并担任H.I.T。的董事会董事。他还在InStent Inc.、Influence Medical Technologies Ltd.和Disc-O-Tech Medical Technologies Ltd.的任职。Ben-Dror博士是以色列律师协会（Israel Bar）的成员，并在加州大学伯克利分校（University of California, Berkeley）法学院获得法理学博士学位。
Yoav Ben Dror was appointed to our Board of Directors and was elected to serve as Non-Executive Vice Chairman on December 12 2011. Dr. Ben-Dror was the chairman of Radiancy’s Board since 2006. He is an entrepreneur with more than 30 years of experience in technology, medical devices and financial innovations. He currently serves on the Board of Dagon Batey-Mamguroth Le-Israel Ltd silo houses, Final Inc. (high-frequency financial algorithm technology), Fitango Inc. (social network), Neurotech Solutions Ltd. (human cognition and behavior with an emphasis on attention deficit/hyperactivity disorder (ADHD)), Travelsys4u Ltd. (a personal mobility system for senior citizens), Impact First Investments Ltd. (investment management firm that specializes in social investing), and Tabit Technologies Ltd. (Formerly: My InPact Solutions Ltd.) (Mobile solutions for restaurant management). He is a director at Keren Shemesh Foundation for the Encouragement of Young Entrepreneurs (in association with YBI (Youth Business International), a foundation assisting young entrepreneurs in transforming an idea into a successful sustainable small business), a director at ANU - making change LTD. (HLZ) (social activity), a director at Hatnuah Hezrachit Hachadasha Ltd. (social activity), and a trustee at the Hecht-Zilzer Trust (charity). Dr. Ben Dror previously served on the Board of Cellcom Israel Ltd. (CEL-NYSE), Dubek Ltd. (tobacco), Magic Box Ltd. (financial algorithm technology) and Holon Institute of Technology (H.I.T.), and was a member of the Board of Trustees of the Holon Institute of Technology (H.I.T.). He was one of the founders of Amphorae Vineyard Ltd. (Winery - Israel). He was also involved with InStent Inc., Influence Medical Technologies Ltd. and Disc-O-Tech Medical Technologies Ltd. Dr. Ben Dror is a member of the Israel Bar and holds a Doctor of the Science of Jurisprudence (J.S.D.) from the School of Law (Boalt Hall), University of California, Berkeley. - Yoav Ben Dror被任命为我司董事，并于2011年12月12日被选为董事会非执行副主席。Ben-Dror博士从2006年开始担任Radiancy的董事会主席。他是一位拥有超过30年技术、医疗设备与金融创新领域经验的企业家。他目前担任以下公司的董事：Dagon Batey-Mamguroth Le-Israel Ltd silo houses, Final Inc.（高频金融算法技术）， Fitango Inc.（社交网络），Neurotech Solutions Ltd.（专注于多动症的人类认知与行为），和Impact First Investments Ltd.（专注于社会投资的投资管理公司）。他担任支持青年企业家的Keren Shemesh基金会（其与青年商业国际（Youth Business International，YBI ）合作，后者为帮助青年企业家将想法转变为成功的且可持续的小型企业的基金会）董事，担任Hatnuah Hezrachit Hachadasha Ltd.的董事（社交活动），担任Hecht-Zilzer Trust（慈善机构）的理事。在这之前，Ben-Dror博士担任以下公司的董事：Cellcom Israel Ltd.（纽交所代码：CEL），Dubek Ltd.（烟草公司）与Magic Box Ltd.（金融算法技术公司），并担任以色列霍龙工学院（Holon Institute of Technology，H.I.T.）的校董会董事，并担任H.I.T。的董事会董事。他还在InStent Inc.、Influence Medical Technologies Ltd.和Disc-O-Tech Medical Technologies Ltd.的任职。Ben-Dror博士是以色列律师协会（Israel Bar）的成员，并在加州大学伯克利分校（University of California, Berkeley）法学院获得法理学博士学位。
- Yoav Ben Dror was appointed to our Board of Directors and was elected to serve as Non-Executive Vice Chairman on December 12 2011. Dr. Ben-Dror was the chairman of Radiancy’s Board since 2006. He is an entrepreneur with more than 30 years of experience in technology, medical devices and financial innovations. He currently serves on the Board of Dagon Batey-Mamguroth Le-Israel Ltd silo houses, Final Inc. (high-frequency financial algorithm technology), Fitango Inc. (social network), Neurotech Solutions Ltd. (human cognition and behavior with an emphasis on attention deficit/hyperactivity disorder (ADHD)), Travelsys4u Ltd. (a personal mobility system for senior citizens), Impact First Investments Ltd. (investment management firm that specializes in social investing), and Tabit Technologies Ltd. (Formerly: My InPact Solutions Ltd.) (Mobile solutions for restaurant management). He is a director at Keren Shemesh Foundation for the Encouragement of Young Entrepreneurs (in association with YBI (Youth Business International), a foundation assisting young entrepreneurs in transforming an idea into a successful sustainable small business), a director at ANU - making change LTD. (HLZ) (social activity), a director at Hatnuah Hezrachit Hachadasha Ltd. (social activity), and a trustee at the Hecht-Zilzer Trust (charity). Dr. Ben Dror previously served on the Board of Cellcom Israel Ltd. (CEL-NYSE), Dubek Ltd. (tobacco), Magic Box Ltd. (financial algorithm technology) and Holon Institute of Technology (H.I.T.), and was a member of the Board of Trustees of the Holon Institute of Technology (H.I.T.). He was one of the founders of Amphorae Vineyard Ltd. (Winery - Israel). He was also involved with InStent Inc., Influence Medical Technologies Ltd. and Disc-O-Tech Medical Technologies Ltd. Dr. Ben Dror is a member of the Israel Bar and holds a Doctor of the Science of Jurisprudence (J.S.D.) from the School of Law (Boalt Hall), University of California, Berkeley.
- Dolev Rafaeli
-
Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel. - Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
- Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.
高管简历
中英对照 | 中文 | 英文- Dennis M. McGrath
Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
Dennis M. McGrath,has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial-stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), Cagent Vascular, LLC and BioVector, Inc. Formerly from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and as Chairman of the Board of Trustees of Manor College.- Dennis M. McGrath于2019年3月起担任PAVmed（纳斯达克股票代码：PAVM）——一家处于多元化商业阶段的医疗技术公司——的总裁（于2017年3月至2019年3月担任副总裁执行Dennis M. McGrath），并于2017年3月起担任PAVmed的首席财务官首席财务官。自Lucid完成首次公开募股后，McGrath先生还担任过Lucid的首席财务官，Lucid是PAVmed的控股子公司。在此之前，McGrath先生于2000年至2017年在PhotoMedex，Inc.（前身为Nasdaq：PHMD）担任多个高级职位，该公司是一家全球医疗设备和服务制造商和分销商，包括于2011年至2017年担任董事、总裁兼首席财务官。在PhotoMedex于2011年12月与Radiancy，Inc反向收购之前，他还曾于2009年至2011年担任董事会成员兼首席执行官，并于2000年至2009年担任财务副总裁兼首席财务官。他以P.A.C.（费城资本与技术联盟）入围2011年度最佳投资交易、SmartCEO杂志2012年度最佳转型公司首席执行官、安永2013年度最佳企业家入围等荣誉获奖。他在国内和国际并购方面拥有丰富的经验，特别是涉及上市公司收购的并购，包括Surgical Laser Technologies，Inc（原纳斯达克代码：SLTI）、ProCyte Corporation（原纳斯达克代码：PRCY）、LCA Vision，Inc.（原纳斯达克代码：LCAV）和Think New Ideas，Inc.（原纳斯达克代码：THNK）。在加入PhotoMedex之前，他曾在商业咨询和技术整合公司AnswerThink Consulting Group，Inc.（当时的纳斯达克股票代码：ANSR，现在的哈克特集团，纳斯达克股票代码：HCKT）担任多个高级职位，其中1999年至2000年担任AnswerThink Consulting Group，Inc.最大部门Internet Practice的首席运营官，在两家公司合并期间，他同时担任Think New Ideas，Inc.（当时的纳斯达克股票代码：THNK，现纳斯达克股票代码：HCKT）的代理首席财务官，这是一家交互式营销服务和商业解决方案公司。McGrath先生还于1996年至1999年担任TriSpan，Inc.的首席财务官、执行副总裁兼董事。TriSpan，Inc.是一家互联网商务解决方案和技术咨询公司，该公司于1999年被AnswerThink Consulting Group，Inc.收购。在Arthur Andersen & Co.任职期间，他开始了自己的职业生涯，1981年成为一名注册会计师，并以优异成绩获得拉萨尔大学会计学学士学位。此外，他还担任审计和薪酬委员会主席以及多家医疗器械公司的董事，包括DarioHealth Corp.（Nasdaq：DRIO）、Cagent Vascular，LLC和BioVector，Inc。McGrath先生曾于2007年至2009年担任Embrella Cardiovascular，Inc.（出售给Edwards Lifesciences Corporation，NYSE：EW）的董事。他还担任泰勒大学访客委员会成员和马诺学院董事会主席。
- Dennis M. McGrath,has served as the President of PAVmed, Inc. (Nasdaq: PAVM), a diversified commercial-stage medical technology company since March 2019 (having served as Executive Vice President from March 2017 to March 2019) and as PAVmed's Chief Financial Officer since March 2017. Mr. McGrath has also served as the Chief Financial Officer of Lucid, PAVmed's majority owned subsidiary since the consummation of Lucid's initial public offering. Previously, from 2000 to 2017 Mr. McGrath served in several senior level positions of PhotoMedex, Inc. (formerly, Nasdaq: PHMD), a global manufacturer and distributor of medical device equipment and services, including from 2011 to 2017 as director, President, and Chief Financial Officer. Prior to PhotoMedex's reverse merger with Radiancy, Inc in December 2011, he also served as a board member and Chief Executive Officer from 2009 to 2011 and served as Vice President of Finance and Chief Financial Officer from 2000 to 2009. He received honors as a P.A.C.T. (Philadelphia Alliance for Capital and Technology) finalist for the 2011 Investment Deal of the Year, award winner for the SmartCEO Magazine 2012 CEO of the Year for Turnaround Company, and finalist for the Ernst & Young 2013 Entrepreneur of the Year. He has extensive experience in mergers and acquisitions, both domestically and internationally, particularly involving public company acquisitions, including Surgical Laser Technologies, Inc, (formerly, Nasdaq: SLTI), ProCyte Corporation (formerly, Nasdaq: PRCY), LCA Vision, Inc. (formerly, Nasdaq: LCAV) and Think New Ideas, Inc. (formerly, Nasdaq: THNK). Prior to PhotoMedex, he served in several senior level positions of AnswerThink Consulting Group, Inc. (then, Nasdaq: ANSR, now, The Hackett Group, Nasdaq: HCKT), a business consulting and technology integration company, including from 1999 to 2000 as Chief Operating Officer of the Internet Practice, the largest division of AnswerThink Consulting Group, Inc., while concurrently during the merger of the companies, serving as the acting Chief Financial Officer of Think New Ideas, Inc. (then, Nasdaq: THNK, now, Nasdaq: HCKT), an interactive marketing services and business solutions company. Mr. McGrath also served from 1996 until 1999 as Chief Financial Officer, Executive Vice President and director of TriSpan, Inc., an internet commerce solutions and technology consulting company, which was acquired by AnswerThink Consulting Group, Inc. in 1999. During his tenure at Arthur Andersen & Co., where he began his career, he became a Certified Public Accountant in 1981 and he holds a B.S., maxima cum laude, in accounting from LaSalle University. In addition, he serves as the audit and compensation committee chair and a director of several medical device companies, including DarioHealth Corp. (Nasdaq: DRIO), Cagent Vascular, LLC and BioVector, Inc. Formerly from 2007 to 2009, Mr. McGrath served as a director of Embrella Cardiovascular, Inc. (sold to Edwards Lifesciences Corporation, NYSE: EW). He also serves on the Board of Visitors for Taylor University and as Chairman of the Board of Trustees of Manor College.
- Dolev Rafaeli
Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.- Dolev Rafaeli于2011年12月被任命为首席执行官兼董事。Rafaeli博士于2006年2月加入Radiancy担任总裁兼首席执行官。他拥有超过25年的管理国际运营的经验。加入Radiancy前，从2004年到2006年，Rafaeli博士担任USR Group的总裁兼首席执行官，管理以色列、中国、中国香港和美国的营业部，这是一家消费者电子产品制造商。从2000年到2004年，Rafaeli博士创立奥宝科技公司（Orbotech Ltd.）并担任其总经理，纳斯达克代码：ORBK，这是一家为中国和中国香港的电子行业生产自动光学检测固定设备的制造商，他在那里为将这些业务打造为年入1亿美元的业务做出贡献。从1997年到2000年，Rafaeli博士担任USR Ltd.的首席执行官，这是一家全球性的电子合同制造公司，其为多个通信、消费者和医疗设备领域提供设计、供应链与制造服务。USR Ltd.雇佣大约1000人雇员。在这之前，Rafaeli博士在摩托罗拉（Motorola）的年收入超过4亿美元的陆地移动产品解决方案部门、制造与分布通信、消费者和其他基础设施电子产品担任其运营部总监和阿拉德制造工厂的经理。Rafaeli博士毕业于以色列理工大学（Technion-Israel Institute of Technology），获得工业工程与管理学理学学士学位和运营管理理科硕士学位，并获得美国世纪大学（Century University）商业管理博士学位。
- Dolev Rafaeli STRATA Skin Sciences, Inc.'s former Chief Executive Officer, was appointed Interim Chief Executive Officer effective April 10 2018 and became STRATA Skin Sciences, Inc.'s Chief Executive Officer effective on May 29 2018. He resigned effective February 28 2021. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of PhotoMedex, from 2011 until 2020 and was its CEO from 2006 to 2017. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. He also served as General Manager of Orbotech, a technology company used in the manufacturing of consumer and industrial products throughout the electronics and adjacent industries, in China and Hong Kong, and held senior positions at Motorola, a telecom company. Dr. Rafaeli holds a Ph.D. in Business Administration from Century University in New Mexico, an MBA from Cornell University, Masters Degrees from the Technion in Haifa, Israel and a B.Sc. in Industrial Engineering and Management from the Technion in Israel.